Overview
Protein Replacement Therapy (PRT) offers a therapeutic approach for rare diseases caused by missing, deficient, or dysfunctional proteins. By supplying functional proteins or enabling their production within the body, these therapies aim to restore biological processes and address underlying disease mechanisms.
Advances in recombinant protein engineering, enzyme replacement, mRNA delivery, and nanotechnology are expanding the range of potential treatment strategies. However, challenges involving protein stability, targeted delivery, manufacturing costs, and sustained therapeutic efficacy remain important considerations in developing accessible treatments for rare disease populations.
This white paper explores approaches to developing protein replacement therapies, enzyme replacement, and mRNA-based treatments, as well as recent commercial trends and clinical programs shaping rare disease care.
Key Insights You’ll Gain
How Stellarix Can Help
Stellarix works with life sciences organizations identify lucrative opportunities in rare disease therapeutics through technology intelligence, regulatory and risk advisory, and strategic alliance advisory. We help them assess protein engineering and mRNA delivery platforms, evaluate enzyme replacement approaches, and map emerging treatment pipelines to guide development priorities and effective partnership decisions.
